Bausch Health Companies (BHC) to Release Quarterly Earnings on Thursday

Bausch Health Companies (NYSE:BHC) is set to issue its quarterly earnings data before the market opens on Thursday, May 2nd. Analysts expect the company to announce earnings of $0.74 per share for the quarter. Bausch Health Companies has set its FY 2024 guidance at EPS.Individual that wish to register for the company’s earnings conference call can do so using this link.

Bausch Health Companies (NYSE:BHC) last released its earnings results on Thursday, February 22nd. The company reported $1.15 EPS for the quarter, topping the consensus estimate of $1.01 by $0.14. The firm had revenue of $2.41 billion during the quarter, compared to analysts’ expectations of $2.29 billion. Bausch Health Companies had a positive return on equity of 5,147.48% and a negative net margin of 6.76%. Bausch Health Companies’s revenue for the quarter was up 9.8% on a year-over-year basis. During the same period in the previous year, the firm posted $1.02 EPS. On average, analysts expect Bausch Health Companies to post $4 EPS for the current fiscal year and $4 EPS for the next fiscal year.

Bausch Health Companies Price Performance

BHC stock opened at $8.57 on Thursday. The business’s 50-day moving average is $9.29 and its two-hundred day moving average is $8.16. The firm has a market capitalization of $3.13 billion, a P/E ratio of -5.29 and a beta of 0.85. Bausch Health Companies has a 1 year low of $5.57 and a 1 year high of $11.46.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on BHC shares. Royal Bank of Canada decreased their price target on shares of Bausch Health Companies from $12.00 to $11.00 and set a “sector perform” rating for the company in a research note on Tuesday. Jefferies Financial Group reduced their price objective on shares of Bausch Health Companies from $16.00 to $14.00 and set a “buy” rating on the stock in a report on Tuesday, February 20th. Finally, StockNews.com upgraded shares of Bausch Health Companies from a “hold” rating to a “buy” rating in a research note on Wednesday, February 7th.

About Bausch Health Companies

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.